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ABSTRACT
Background: Human papillomavirus-positive (HPVþ) base of tongue squamous cell carcinoma
(BOTSCC) has a better outcome than corresponding HPV cancer. TLR5 and TLR7 expression was
previously shown to differ depending on HPV status and correlate with outcome in oropharyngeal
squamous cell carcinoma.
Aims/objectives: For validation, TLR5 and TLR7 were analyzed in a BOTSCC-cohort for correlation with
HPV, survival, CD4þ and CD8þ tumor-infiltrating lymphocyte (TIL) counts, the latter being a well-
documented prognostic marker.
Materials and methods: BOTSCC biopsies, (49HPVþ/28HPV) were analyzed by immunohistochemistry
for TLR5 and TLR7, and correlated with the above parameters.
Results: TLR5 expression was more frequently absent/weak than medium/strong in HPVþ compared
to HPV BOTSCC (p< .001). The opposite was observed for TLR7 (p< .007). TLR5 and TLR7 expression
did not correlate to survival in either the HPV or HPVþ cases, or to CD4þ TILs. TLR5, (but not TLR7)
expression was correlated to CD8þ TIL counts (p¼ .023).
Conclusion and significance: Absent/weak TLR5 and medium/strong TLR7 expression was validated
as more frequent in HPVþ compared with HPV BOTSCC. A correlation between CD8þ TIL counts, and
TLR5 expression was disclosed, but not with TLR7. Therefore, it could be useful to investigate TLR7 fur-
ther as a potential independent prognostic marker.
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Patients with human papillomavirus-positive (HPVþ)
oropharyngeal squamous cell carcinoma (OPSCC) have a
much more favorable clinical outcome than those with HPV
negative (HPV) OPSCC [1–3]. In the Western world the
incidences of tonsillar and base of tongue squamous cell
carcinoma (TSCC/BOTSCC), the OPSCC subtypes where
HPV is most common, have increased [4–7]. Notably, treat-
ment for head and neck squamous cell carcinoma include
chemo-radiotherapy, targeted therapy, and surgery either
alone or in combination. These treatment modalities expose
the patients to risks of therapy-related side effects and
complications. Most HPVþ TSCC/BOTSCC patients do not
need intensified treatment, and to de-escalate treatment and
reduce side effects, would be of benefit for most patients
[3,8,9]. To identify patients who will respond readily to
protocol treatment, attempts have been made to find
additional predictive markers, e.g. age, stage, high CD8þ
tumor-infiltrating lymphocyte (TIL) counts, HPV16 E2
mRNA expression, absent/weak CD44, or high LRIG1 or
CD98 expression and use mathematical models [3,9–14]. In
addition, we recently explored the impact of Toll-like recep-
tors (TLR) in OPSCC and their influence on survival [15].
In that study tumor biopsies of 202 OPSCC diagnosed in
Helsinki, Finland, were analyzed for the presence of TLR5, 7
and 9, and the expression of some of these TLRs was corre-
lated with clinical outcome. TLR5, 7 and 9 expression
differed between HPVþ and HPV OPSCC, and in general
HPVþ OPSCC exhibited lower TLR5 and higher TLR7
expression levels than HPV OPSCC [15]. Furthermore,
high expression of TLR5 and low expression of TLR7 corre-
lated with worse disease-specific survival (DSS) in HPVþ
OPSCC [15]. To validate the data in a new cohort in
another Nordic population and in a specific OPSCC subsite,
biopsies from 77 BOTSCC patients from Stockholm,
Sweden, were analyzed for TLR5 and TLR7 expression and
the data were correlated with clinical outcome. Since TLRs
initiate immune responses [15–17], we also examined if
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TLR5 and/or TLR7 expression was correlated with CD4þ
and/or CD8þ TIL counts in the tumors, because the pres-
ence of high CD8þ TIL counts is reported to be a good
prognostic marker in HPVþ OPSCC [9,12,13].
Materials and methods
Patients and tumor characteristics
Patients diagnosed from 2000 to 2011 at the Karolinska
University Hospital with BOTSCC (ICD-10 code C01.9),
were analyzed for TLR5 and TLR7 expression by immuno-
histochemistry (IHC) in order to retrospectively compare
TLR5 and TLR7 expression in patients with HPVþ and
HPV tumors. Details of the patients and their tumors are
presented in Table 1 together with p values. HPVþ
BOTSCC was defined as having an HPV DNA positive
tumor with p16INK4A overexpression (p16þ) [18]. In total,
49 HPVþ BOTSCCs and 28 HPV BOTSCCs fulfilling these
criteria according to our previous studies [5,7,14] were ana-
lyzed for TLR5 and TLR7 expression [15]. The study was
performed in compliance with permission (2009/1278-31/4)
granted by the Regional Ethical Review Board in Stockholm.
Analysis of HPV DNA, p16 overexpression, and CD41
and CD81 TILs
All samples had been tested for HPV DNA by a PCR-based
bead-based multiplex-assay on a MagPix instrument
(Luminex Inc.) as described before [19]. p16 had been
assayed using the monoclonal antibody (mAb) clone JC8
(Santa Cruz Biotech, Santa Cruz, CA), or the E6H4
TM
mouse
mAb clone (CINtecVR , Ventana, Tucson, AZ) and CD4þ and
CD8þ with the mAb clone 1FC and 4B11 respectively,
(Leica Biosystems, Wetzlar, Germany) [19].
Immunohistochemistry for TLR 5 and 7
TLR5 and 7 expression by IHC on 4 lm FFPE sections were
investigated and has been reported before [15]. Monoclonal
mouse anti-human TLR5 (1:200, IMG-664A Imgenex) and
monoclonal rabbit anti-human TLR7 (1:300, IMG-581A
Imgenex) were used. All tissue samples were evaluated separ-
ately for TLR5 and 7 expression by light microscopy, by two
researchers (LH and AN), of which the latter is a resident in
surgical pathology. The samples were evaluated independently,
without the knowledge of clinical parameters. The scoring of
the two researchers was similar in the majority of the cases,
and when not, a consensus was reached. TLR5 intensity, mainly
localized to the cell membranes, was scored as: absent (0),
weak (1), medium (2), and strong (3). TLR7 intensity, mainly
localized to the nuclear membrane and nucleus, was scored as
absent (0) if no TLR7 was observed, weak (1) if some nuclear
membranes were positive, medium (2) if all nuclear membranes
and some nuclei were stained, and strong (3) if nuclear mem-
branes and nuclei were stained substantially. Cases, where the
staining was not possible to be evaluated, were excluded.
Statistical analysis
Categorical variables (e.g. TLR5 and TLR7 expression by
IHC) were compared with the Chi2-test or Fisher’s exact
test, and continuous variables (CD8þ TIL counts) with
Student’s t-test. Clinical outcome was measured as 3-year
disease-free survival (DFS) or 3-year disease-specific survival
(DSS). Only patients treated with intent to cure were
included in the analysis. All patients were followed up for
3-years and then censored. DFS was defined as the time
from diagnosis until date of relapse in disease. Patients
being never tumor-free were censored on day 0, while
patients dying without prior recurrence were censored at
the time-point, when assessing DFS. DSS was defined as the
time from diagnosis until date of relapse or death with the
disease. Survival curves with 3-year DFS and DSS were cal-
culated using the Kaplan–Meier method and differences in
survival were tested using the log-rank test. All statistical
tests were performed using SPSS (SPSS Statistics for Mac,
Version 25. Armonk, NY: IBM Corp.).
Results
Analysis of TLR5 and TLR7 expression by IHC in HPV1
and HPV2 BOTSCC
Totally, 49 HPVþ and 28 HPV BOTSCC samples were
examined for the expression of TLR5 and TLR7 by IHC
(Table 1). Absent/weak TLR5 staining was observed in 41/
49 (84%) HPVþ BOTSCC and 12/28 (43%) of HPV
BOTSCC (p< .0001). In contrast, TLR7 was more often
absent/weak in HPV BOTSCC (26/28, 93%) as compared
with HPVþ BOTSCC (32/49, 65%) (p¼ .007).
TLR5 and TLR7 expression, and CD81 TILs, in relation
to outcome in HPV1 and HPV2 BOTSCC
The presence of absent/weak TLR5 and TLR7 expression
was then correlated with prognosis among the 68 patients in
the whole cohort, and separately among the 47 patients with
HPVþ BOTSCC, and the 21 patients with HPV BOTSCC,
who had been treated with curative intent, although in the
latter group the patient number was limited.
In all the examined cases, absent/weak TLR5 or TLR7
did not have a statistically significant correlation with clin-
ical outcome defined as OS, DFS or DSS. For HPVþ
BOTSCC, Kaplan–Meier graphs for DFS and DSS are
depicted for absent/weak and moderate/high TLR5 expres-
sion, as well as for absent/weak and moderate/high TLR7
expression in Figure 1.
TLR5 and TLR7 expression in correlation to CD81 and
CD41 TIL counts
The presence of TLR5 and TLR7 expression in correlation
with CD4þ and CD8þ TIL counts was examined in all
patients. Patients with absent/weak TLR5 expression had
significantly higher CD8þ TIL counts (p¼ .023), but no cor-
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addition, for patients with HPVþ BOTSCC the correlation
between absent/weak TLR5 expression and high CD8þ TIL
counts remained (p¼ .038), while this was not the case for
corresponding HPV BOTSCC cases p¼ .92. No correlation
could be observed either between TLR7 expression and
CD4þ TIL or CD8þ TIL counts (p¼ .43 and p¼ .58,
respectively), or when dichotomizing the patients into those
with HPVþ or HPV BOTSCC (p¼ .17 and p¼ .94,
respectively).
Discussion
This study aimed to validate whether TLR5 and TLR7
expression differed between HPVþ and HPV BOTSCC (i.e.
in a specific subtype of OPSCC), as has been previously
shown in HPVþ and HPV OPSCC and whether TLR5 and
TLR7 expression would correlate with survival in HPVþ
BOTSCC [15]. Our results confirmed that absent/weak
TLR5 and medium/strong TLR7 expression was more fre-
quently found in HPVþ compared with HPV
BOTSCC [15,20].
However, it was not possible to confirm with statistical
significance that moderate/strong TLR5 or absent/weak
TLR7 expression would correlate with worse outcome irre-
spective of tumor HPV status. TLR5 and TLR7 expression
was also analyzed for correlation with CD4þ and CD8þ TIL
counts and a statistically significant correlation between
absent/weak TLR5 expression and the presence of high
CD8þ TIL counts in all patients, as well as in patients with
HPVþ BOTSCC, was shown. There was, however, no correl-
ation either between TLR7 expression and CD8þ TIL counts
or between CD4þ TIL counts, and TLR5 and
TLR7 expression.
Consequently, in this Scandinavian BOTSCC cohort, we
confirmed similar results compared with the previous study
in an OPSCC cohort [15] stating that the expression of
TLR5 and TLR7 varied according to HPV status, but not
that moderate/strong TLR5 and absent/weak TLR7 expres-
sion correlated with survival. In fact, the trend was the
opposite for DSS and TLR7 expression. The reasons for the
latter discrepancies in clinical outcome and TLR5 and TLR7
expression between this study and the aforementioned study
on OPSCC are unknown. The most plausible explanation
could be that in this study the number of events was limited
due to the favorable outcome for patients with HPVþ
BOTSCC. Furthermore, the limited size of the cohort had
an obvious effect on possibilities to encounter such events
[15]. Nevertheless, as discussed further below, the potential
role of TLR7 expression on survival should be studied fur-
ther in a larger HPVþ BOTSCC cohort, and if possible with
proteomic and transcriptomic analysis.
For HPV BOTSCC no correlation between TLR5 and
TLR7 expression was found, similarly to previously reported
results [15]. This could, however, be due to that in our
study the number of HPV cases were limited.
In this report, TLR5 and TLR7 expression was also inves-
tigated for possible correlation with the presence of CD4þ




























































































Disease specific survival (DSS)
(a) (b)
(c) (d)
p = 0.54 p = 0.61
p = 0.051 p = 0.51
Figure 1. Kaplan–Meier curves with 3-year disease-specific survival (DSS) and 3-year disease-free survival (DFS) for patients with HPVþ BOTSCC stratified for
absent/weak vs. medium/strong TLR5 expression (A and B) and absent/weak vs. medium/strong TLR7 expression (C and D). Differences in survival was analyzed
with the log-rank test. No differences in survival were observed (TLR5 DSS: p¼ .54; TLR5 DFS: p¼ .61; TLR7 DSS: p¼ .051; TLR7 DFS: p¼ .51).
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patterns, which can initiate immunological defense mecha-
nisms against bacteria and viruses [17]. High CD8þ TIL
counts correlated with absent/weak TLR5 expression. This
finding was not entirely unexpected since both absent/weak
TLR5 expression, as well as high CD8þ TIL counts, are cor-
related with the presence of HPV [11,15].
There are some limitations in this study. Here, only
BOTSCC samples were examined and no TSCC cases were
included. More importantly, this gave us an opportunity to
really focus on one tumor subtype and clearly, the associ-
ation between absent/weak TLR5 and medium/strong TLR7
expression with HPV positivity remained. This confirms
that the HPVþ and HPV BOTSCC behave differently
regarding their immunological response, and thus are justly
separated to different entities according to the latest WHO
Head and Neck Pathology book (WHO Classification of
Head and Neck tumors, Lyon 2017). Furthermore, due to
the few events in this cohort among the HPVþ BOTSCC
cases, we could not evaluate the correlation of the expres-
sion results with survival.
To conclude, in accordance with previous studies we
could validate and confirm the presence of absent/weak
TLR5 and medium/strong TLR7 expression in the HPVþ
BOTSCC subtype, but not their correlation with clinical out-
come. However, since TLR7 expression contrary to TLR5,
was not correlated to CD8þ TIL counts, which itself being a
very strong predictive marker, more studies on TLR7 as a
prognostic marker are warranted.
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